Neurocrine Biosciences Inc NBIX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if NBIX is a good fit for your portfolio.
News
-
Neurocrine Biosciences Launches WHAT THE C@H?! Educational Initiative to Support Congenital Adrenal Hyperplasia Community
-
Neurocrine Biosciences Reports Positive Phase 2 Data for NBI-1065845 in Adults with Major Depressive Disorder
-
Sentia Medical Sciences and Neurocrine Biosciences Extend Research Collaboration to Discover Novel CRF Peptides
-
Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2024 Financial Results
-
Neurocrine Biosciences Announces First-Patient Dosed in Phase 2 Clinical Study Evaluating NBI-1070770 in Adults with Major Depressive Disorder
-
Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1065890, a Second-Generation VMAT2 Inhibitor, in Healthy Adults
-
Neurocrine Biosciences to Participate at Virtual Investor Conferences in March
-
Neurocrine Biosciences to Participate at Investor Conferences in March
Trading Information
- Previous Close Price
- $138.97
- Day Range
- $136.06–139.37
- 52-Week Range
- $89.04–148.37
- Bid/Ask
- $134.00 / $143.12
- Market Cap
- $13.86 Bil
- Volume/Avg
- 706,042 / 904,807
Key Statistics
- Price/Earnings (Normalized)
- 28.06
- Price/Sales
- 7.50
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Neurocrine Biosciences Inc is a research-based pharmaceutical company advancing drug candidates in the central nervous system and endocrine-related categories. The company's three late stage clinical programs are elagolix which is hormone releasing antagonist for women's health, opicapone which is an inhibitor for parkinson's patients, and ingrezza for tourette syndrome.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Mid Growth
- Total Number of Employees
- 1,400
- Website
- https://www.neurocrine.com
Competitors
Valuation
|
Metric
|
NBIX
|
SNY
|
TEVA
|
|---|---|---|---|
Price/Earnings (Normalized) | 28.06 | 10.04 | 4.99 |
Price/Book Value | 6.19 | 1.56 | 1.91 |
Price/Sales | 7.50 | 2.38 | 0.90 |
Price/Cash Flow | 39.12 | 11.66 | 9.93 |
Price/Earnings
NBIX
SNY
TEVA
Financial Strength
|
Metric
|
NBIX
|
SNY
|
TEVA
|
|---|---|---|---|
Quick Ratio | 2.25 | 0.83 | 0.54 |
Current Ratio | 2.45 | 1.27 | 1.02 |
Interest Coverage | 73.20 | 11.03 | 0.39 |
Quick Ratio
NBIX
SNY
TEVA
Profitability
|
Metric
|
NBIX
|
SNY
|
TEVA
|
|---|---|---|---|
Return on Assets (Normalized) | 14.51% | 8.05% | 6.70% |
Return on Equity (Normalized) | 20.57% | 14.38% | 39.00% |
Return on Invested Capital (Normalized) | 17.92% | 10.85% | 13.54% |
Return on Assets
NBIX
SNY
TEVA
Drug Manufacturers - Specialty & Generic Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
MKKGY
| Merck KGaA ADR | Snvcprnq | Hshmdwx | $70.9 Bil | |
ZTS
| Zoetis Inc Class A | Tkylbzxfyp | Qxzm | $68.9 Bil | |
HLN
| Haleon PLC ADR | Zdkycjqb | Clzl | $37.5 Bil | |
TEVA
| Teva Pharmaceutical Industries Ltd ADR | Fgvpxvg | Rvp | $14.7 Bil | |
VTRS
| Viatris Inc | Szsvjytv | Drz | $13.7 Bil | |
RDY
| Dr Reddy's Laboratories Ltd ADR | Fwqbhsdvl | Kkb | $11.9 Bil | |
CTLT
| Catalent Inc | Txcthllcj | Mlcyzsj | $10.1 Bil | |
PRGO
| Perrigo Co PLC | Ccgrcndzy | Jkyk | $4.1 Bil | |
CURLF
| Curaleaf Holdings Inc | Cgjbdcdr | Nsc | $3.6 Bil | |
PBH
| Prestige Consumer Healthcare Inc | Ftfnjcfjj | Mvfvmxs | $3.5 Bil |